Trials / Not Yet Recruiting
Not Yet RecruitingNCT07415044
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,431 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally. The study will last up to approximately 108 weeks, excluding screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY4268989 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2030-06-01
- Completion
- 2031-07-01
- First posted
- 2026-02-17
- Last updated
- 2026-03-19
Locations
241 sites across 28 countries: United States, Argentina, Brazil, Canada, China, Colombia, Croatia, Czechia, France, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Poland, Portugal, Puerto Rico, Serbia, Slovakia, South Africa, South Korea, Taiwan, Turkey (Türkiye), Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07415044. Inclusion in this directory is not an endorsement.